Form 4: IRADIMED CEO Sells $413K in Stock via 10b5-1 Plan

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock for approximately $413,282 through a pre-arranged 10b5-1 trading plan.

Summary

• Roger E. Susi, who serves as Director, 10% Owner, CEO, President, and Chairman of IRADIMED CORP (IRMD), reported the sale of common stock.
• The transactions involved the disposition of 5,000 shares of common stock on November 3, 2025.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Susi on June 16, 2025.
• The shares were sold in multiple trades at weighted average prices ranging from $79.82 to $84.60 per share.
• The total value of the shares sold amounts to approximately $413,282.
• Following these transactions, Mr. Susi indirectly beneficially owns 2,322,500 shares through the Phillip Susi 2008 Dynasty Trust.
• Additionally, Mr. Susi indirectly holds 162,950 shares through the Roger E. Susi Revocable Trust and 2,062,500 shares through the Matthew Susi 2008 Dynasty Trust, though he disclaims beneficial ownership of the latter except to the extent of his pecuniary interest.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling by a key executive, but mitigated by the fact that the sales were pre-planned under a 10b5-1 trading plan, which suggests a lack of opportunistic timing.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating pre-planned transactions and reducing concerns about opportunistic insider selling.

Negatives

• The CEO, President, and Chairman of the company, a significant insider, reduced his indirect holdings of common stock.

Future Outlook

NA

Management Comments

• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends.

Corporate Governance

Related Party Transactions

• The sales were made from shares indirectly held through the Phillip Susi 2008 Dynasty Trust.
• Roger E. Susi also indirectly holds shares through the Roger E. Susi Revocable Trust and the Matthew Susi 2008 Dynasty Trust.

Stakeholder Impact

• Shareholders may perceive the sale of shares by a high-ranking insider as a potential signal, although the pre-arranged nature of the 10b5-1 plan mitigates immediate concerns about a lack of confidence in the company's future.

Key Dates

Recommendation

The CEO's sale of shares, while executed under a pre-arranged 10b5-1 plan, represents a reduction in direct insider exposure. While not necessarily a negative signal due to the planned nature and potential personal financial planning reasons, it does not provide a strong catalyst for a 'buy' recommendation. Investors should monitor future filings and company performance, maintaining a 'hold' position based solely on this transaction.

Keywords

IRADIMED, IRMD, Roger E. Susi, insider trading, stock sale, Form 4, 10b5-1 plan, CEO, Director, 10% Owner